Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Shepherd, Frances A
  • Altorki, Nasser K
  • Eberhardt, Wilfried Ernst Erich
  • O'Brien, Mary ER
  • Spigel, David R
  • Crino, Lucio
  • Tsai, Chun-Ming
  • Kim, Joo-Hang
  • Cho, Eun Kyung
  • Szczesna, Aleksandra
  • Burghuber, Otto
  • Hoffman, Philip C
  • Keshavjee, Shafique
  • Orlov, Sergey
  • Serwatowski, Piotr
  • Wang, Jiuzhou
  • Foley, Margaret A
  • Horan, Julie D
  • Richardson, Frank C
  • Kelly, Karen

publication date

  • May 20, 2014